Stryker (SYK) Stock Price
Stryker Price
Over the last 19 years Stryker grew revenue by 8.4% annually, reaching 25.12 B USD. Earnings per share have grown at 8.2% per year over the last 19 years. For Stryker, the net margin of 12.9% is up versus 11.7% a few years ago. At today's price the dividend yield works out to roughly 1.26%. The payout ratio is around 40% of earnings. The dividend has grown at 15.5% per year over the past 19 years. The consensus 12-month price target for Stryker is 380.00 USD, about 40.8% above where the stock trades today. Of 34 analysts, 28 rate the stock a buy — an overall Buy consensus.
Stryker stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Stryker over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Stryker stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Stryker's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Stryker Price |
|---|---|
| 9/11/2026 | 269.80 USD |
| 9/10/2026 | 273.97 USD |
| 9/9/2026 | 275.39 USD |
| 9/8/2026 | 282.09 USD |
| 9/4/2026 | 304.61 USD |
| 9/3/2026 | 307.99 USD |
| 9/2/2026 | 312.19 USD |
| 9/1/2026 | 317.40 USD |
| 8/31/2026 | 326.65 USD |
| 8/28/2026 | 327.36 USD |
| 8/27/2026 | 328.27 USD |
| 8/26/2026 | 329.67 USD |
| 8/25/2026 | 330.59 USD |
| 8/24/2026 | 329.61 USD |
| 8/21/2026 | 329.45 USD |
| 8/20/2026 | 327.70 USD |
| 8/19/2026 | 340.15 USD |
| 8/18/2026 | 335.13 USD |
| 8/14/2026 | 339.21 USD |
| 8/13/2026 | 341.09 USD |
| 8/12/2026 | 347.21 USD |
| 8/11/2026 | 348.15 USD |
| 8/10/2026 | 341.11 USD |
| 8/7/2026 | 339.03 USD |
| 8/6/2026 | 337.43 USD |
| 8/5/2026 | 334.50 USD |
| 8/4/2026 | 335.65 USD |
| 8/3/2026 | 341.20 USD |
| 7/31/2026 | 325.70 USD |
| 7/30/2026 | 348.04 USD |
Stryker Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Stryker Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.95 | 11.33 | 12.44 | 13.60 | 14.88 | 14.35 | 17.11 | 18.45 | 20.50 | 22.60 | 25.12 | 27.30 | 29.70 | 32.01 | 34.88 | 37.89 |
| 2.80 | 13.86 | 9.88 | 9.30 | 9.43 | -3.58 | 19.21 | 7.84 | 11.11 | 10.23 | 11.16 | 8.68 | 8.79 | 7.79 | 8.96 | 8.64 |
| 64.22 | 63.98 | 63.51 | 63.23 | 63.03 | 60.99 | 62.60 | 59.84 | 60.95 | 61.87 | 63.96 | 63.96 | 63.96 | 63.96 | 63.96 | 63.96 |
| 6.39 | 7.25 | 7.90 | 8.60 | 9.38 | 8.75 | 10.71 | 11.04 | 12.49 | 13.98 | 16.07 | 17.46 | 19.00 | 20.48 | 22.31 | 24.24 |
| 2.25 | 2.58 | 2.77 | 3.10 | 3.39 | 3.03 | 3.76 | 3.73 | 4.28 | 5.06 | 4.89 | 7.30 | 8.17 | 9.02 | 9.93 | 10.99 |
| 22.64 | 22.75 | 22.24 | 22.82 | 22.76 | 21.10 | 22.00 | 20.24 | 20.88 | 22.40 | 19.47 | 26.75 | 27.52 | 28.17 | 28.47 | 29.01 |
| 1.44 | 1.65 | 1.02 | 3.55 | 2.08 | 1.60 | 1.99 | 2.36 | 3.17 | 2.99 | 3.25 | 5.81 | 6.48 | 7.21 | 8.03 | 8.93 |
| 179.42 | 14.45 | -38.07 | 248.33 | -41.37 | -23.24 | 24.70 | 18.25 | 34.22 | -5.43 | 8.45 | 78.84 | 11.59 | 11.33 | 11.38 | 11.20 |
| 1.42 | 1.57 | 1.74 | 1.93 | 2.14 | 2.36 | 2.59 | 2.84 | 3.05 | 3.24 | 3.40 | 3.52 | 3.79 | 4.08 | – | – |
| -24.06 | 10.56 | 10.83 | 10.92 | 10.36 | 10.33 | 9.79 | 9.69 | 7.77 | 6.23 | 4.94 | 3.53 | 7.67 | 7.65 | – | – |
| 378.40 | 379.10 | 380.90 | 380.20 | 380.10 | 381.30 | 382.70 | 382.30 | 383.90 | 386.10 | 386.50 | 386.50 | 386.50 | 386.50 | 386.50 | 386.50 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Stryker generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Stryker retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Stryker's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Stryker has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Stryker's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Stryker stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Stryker Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Stryker business model & stock analysis
Stryker SWOT Analysis
Strengths
1. Strong market presence: Stryker Corp is a leading global medical technology company known for its innovative products and solutions.
2. Diverse product portfolio: The company offers a wide range of medical devices, orthopedic implants, surgical equipment, and other healthcare products, enabling it to cater to various healthcare needs.
3. Established brand reputation: Stryker Corp has built a strong brand image over the years, known for its quality, reliability, and advanced technology.
4. Strong financial performance: The company has consistently delivered positive financial results, with significant revenue growth and profitability.
Weaknesses
1. Dependence on key markets: Stryker Corp relies heavily on specific geographic regions for its revenue, making it vulnerable to fluctuations in those markets.
2. Vulnerability to regulations: The medical technology industry is subject to stringent regulations and compliance requirements, which may pose challenges for the company's operations.
3. Limited manufacturing capacity: In some product categories, Stryker Corp may face constraints in scaling up production to meet growing demand.
Opportunities
1. Growing global healthcare market: The increasing healthcare needs, particularly in emerging markets, present opportunities for Stryker Corp to expand its customer base and introduce new products.
2. Technological advancements: Stryker Corp can leverage advancements in areas such as robotics, digital health, and artificial intelligence to develop innovative and differentiated products.
3. Expansion through acquisitions: The company can explore strategic acquisitions to enhance its product offerings, enter new markets, or strengthen its existing market presence.
Threats
1. Intense competition: Stryker Corp operates in a highly competitive market, facing competition from both established medical technology companies and new entrants.
2. Economic instability: Fluctuations in global economic conditions can impact healthcare spending, thereby affecting the demand for Stryker Corp's products.
3. Product recalls or liabilities: Any product recalls or legal liabilities related to the company's products could damage its reputation and result in financial losses.
Stryker Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Stryker Segments
Stryker Revenue by Segment (1/5)
Max
Details
Stryker Revenue by Segment (2/5)
3 Years
5 Years
Max
Details
Stryker Revenue by Segment (3/5)
Max
Details
Stryker Revenue by Segment (4/5)
3 Years
5 Years
10 Years
Max
Details
Stryker Revenue by Segment (5/5)
3 Years
5 Years
Max
Details
Stryker Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Stryker Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Stryker historical P/E ratio, EBIT multiple, and P/S ratio
Stryker annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Stryker shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Stryker stock splits
Stryker Dividend History
30 years of dividend payments · 10 consecutive increases
Stryker dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Stryker dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Stryker forecasts and price targets in September 2026
Analyst Price Targets 2026Stryker Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/13/2026 | Downgrade | OutperformPeer Perform | – | |
| 8/3/2026 | Maintained | Market Outperform | – | |
| 7/31/2026 | Maintained | Hold | – | |
| 7/31/2026 | Maintained | Outperform | 48 | |
| 7/31/2026 | Maintained | Overweight | 48 | |
| 7/31/2026 | Maintained | Overweight | 55 | |
| 7/31/2026 | Maintained | Buy | 49 | |
| 7/9/2026 | Upgrade | Market PerformOutperform | 70 | |
| 7/6/2026 | Maintained | Outperform | 62 | |
| 6/5/2026 | Maintained | Outperform | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Stryker Earnings Calls
Stryker Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 7/30/2026 | 3.52USD | - | 6.64 BUSD | - | 2026 Q2 |
| 4/30/2026 | 3.01USD | - | 6.40 BUSD | - | 2026 Q1 |
| 1/29/2026 | 4.44USD | - | 7.19 BUSD | - | 2025 Q4 |
| 4/29/2024 | 2.56USD | - | 5.17 BUSD | - | 2024 Q1 |
| 1/29/2024 | 3.30USD | - | 5.65 BUSD | - | 2023 Q4 |
| 7/24/2023 | 2.40USD | - | 4.78 BUSD | - | 2023 Q2 |
| 4/26/2023 | 2.16USD | - | 4.54 BUSD | - | 2023 Q1 |
| 1/25/2023 | 2.86USD | - | 5.03 BUSD | - | 2022 Q4 |
| 10/31/2022 | 2.25USD | - | 4.52 BUSD | - | 2022 Q3 |
| 7/26/2022 | 2.30USD | - | 4.60 BUSD | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Stryker stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Stryker shareholder structure
| % | Name |
|---|---|
8.73091% | |
7.14154% | |
5.79125% | |
4.35649% | |
4.28569% | |
4.12369% |
Stryker Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
100.00% | SEC ↗ | |
13.28% | SEC ↗ | |
10.10% | SEC ↗ | |
9.83% | SEC ↗ | |
7.60% | SEC ↗ | |
6.73% | SEC ↗ | |
6.30% | SEC ↗ | |
5.50% | SEC ↗ | |
5.40% | SEC ↗ | |
5.30% | SEC ↗ |
Stryker Executives and Management Board
19 members · avg. age 57 · 37 % women
Mr. Kevin Lobo (60)
Chairman of the Board, President, Chief Executive Officer · since 2011
21.98 M USD
Management
Mr. Spencer Stiles (49)
President, Chief Operating Officer
Mr. J. Andrew Pierce (51)
Group President - MedSurg and Neurotechnology
Mr. Viju Menon (57)
Group President - Global Quality and Operations
Mr. Robert Fletcher (54)
Vice President, Chief Legal Officer
Mr. Preston Wells (48)
Chief Financial Officer, Vice President
Mr. Dylan Crotty (49)
Group President, Orthopaedics
Board of Directors
Ms. Sherilyn Mccoy (67)
Lead Independent Director
Mr. Andrew Silvernail (54)
Independent Director
Ms. Mary Brainerd (71)
Independent Director
Dr. Giovanni Caforio (60)
Independent Director
Ms. Lisa Skeete Tatum (57)
Independent Director
Ms. Ronda Stryker (70)
Independent Director
Stryker Supply Chain
Stryker Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.46 | 0.37 | 0.90 | ||
| 2 | 0.18 | 0.38 | 0.89 | ||
| 3 | 0.12 | 0.39 | 0.86 | ||
| 4 | 0.33 | -0.09 | 0.86 | ||
| 5 | 0.42 | -0.11 | 0.85 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | Apria, Inc. | -0.17 | -0.05 | — | |
| 2 | 0.08 | — | — | ||
| 3 | 0.03 | — | — | ||
| 4 | -0.09 | — | — | ||
| 5 | 0.11 | -0.19 | — |
Frequently asked questions about Stryker
The business model of Stryker Corp focuses on providing innovative medical technologies and solutions worldwide. As a leading medical technology company, Stryker Corp specializes in products and services across various segments, including orthopedics, medical and surgical, neurotechnology, and spine. With a strong emphasis on research and development, Stryker Corp strives to deliver advanced and effective healthcare solutions to improve patient outcomes. The company's commitment to innovation, quality, and customer satisfaction has made it a trusted name in the medical industry. Stryker Corp's business model revolves around leveraging its expertise and cutting-edge technologies to meet the evolving needs of healthcare professionals and enhance the lives of patients.
Stryker Corp is primarily active in the healthcare industry.
The main competitors of Stryker Corp in the market are Johnson & Johnson, Medtronic, Zimmer Biomet Holdings, and Boston Scientific.
Stryker Corp is a renowned American medical technology company established in 1941. With over 80 years of experience, Stryker has evolved into a global leader specializing in surgical equipment and orthopedic implants. The company's roots trace back to its founding by Dr. Homer Stryker, an innovative orthopedic surgeon who developed various medical devices. Today, Stryker Corp offers a wide range of products across multiple medical disciplines, including reconstructive devices, neurotechnology, spine systems, and more. The company's commitment to innovation, coupled with strategic acquisitions, has solidified its position as a trusted name in the medical industry.
Stryker Corp has achieved significant milestones throughout its history. A major accomplishment for the company was the development and introduction of the first-ever surgical navigation system, the Navigation System II. This technology revolutionized surgical procedures by providing real-time imaging and guidance to surgeons, improving precision and patient outcomes. Another notable milestone for Stryker Corp was the acquisition of Howmedica, a leading orthopedic company, in 1998. This strategic move further strengthened Stryker Corp's position in the medical technology industry, enhancing its product portfolio and global presence. Over the years, the company has continued to innovate and has been recognized for its advancements in medical devices and solutions.
Stryker Corp is primarily present in various countries and regions worldwide. Some of the key locations include the United States, where the company is headquartered in Kalamazoo, Michigan. Additionally, Stryker has a significant presence in Europe, with operations in countries such as Germany, France, the United Kingdom, Italy, and Switzerland. The company is also active in the Asia-Pacific region, specifically in countries like China, Japan, India, and Australia. With its global reach, Stryker Corp ensures its innovative medical technologies and products are available to healthcare professionals and patients across different parts of the world.
Stryker Corp represents values of innovation, integrity, and excellence in the medical technology industry. The company's corporate philosophy centers around delivering high-quality products and services that improve patient outcomes and enhance healthcare providers' capabilities. By continually investing in research and development, Stryker strives to introduce cutting-edge solutions that address critical healthcare needs and promote sustainable growth. With a commitment to ethical business practices and global collaboration, Stryker focuses on delivering value to its stakeholders, including healthcare professionals, patients, employees, and shareholders. Stryker Corp's dedication to advancing medical technology and improving lives embodies its core values and corporate philosophy.
Analysts currently set an average price target of 382.61 USD for the Stryker stock (median: 380.00 USD), implying +40.6 % versus the latest price. The consensus is based on 34 analyst ratings.
34 analysts currently rate the Stryker stock: 28 recommend buying, 6 holding and 0 selling. For 2026, analysts expect Stryker to generate revenue of 27.30 B USD and earnings per share of 15.02 USD.
Converted at the current exchange rate, the Stryker share trades at 232.57 EUR (269.80 USD).
The Stryker share (SYK) is listed on 12 stock exchanges, including: NYSE (SYK), XETRA (SYK.DE), Frankfurt (SYK.F), München (SYK.MU), Stuttgart (SYK.SG), Düsseldorf (SYK.DU), Berlin (SYK.BE), London (0R2S.L).
Stryker Corp is a US-American company that specializes in the manufacturing and sale of medical devices, implantable products, and medical services. The company was founded in 1941 and has since become a leading company in the medical technology industry. Stryker has four business segments, namely Medical Devices, Orthopedics, Medical and Surgical Instruments, and Neurotechnology and Spine Products. In the Medical Devices segment, Stryker offers a wide range of products including endoscopy devices, respiratory devices, patient monitoring devices, neurological monitoring devices, and medical lighting systems. These products are used in hospitals and clinical facilities for patient diagnosis and treatment. In Orthopedics, Stryker is one of the world leaders in implants and instruments for joint surgery. The company offers products for the hip, knee, shoulder, wrist, and other joints. Stryker has also taken a leading role in introducing robotics in surgery in this field. The Mako robot allows for precise implantations, enabling patients to have faster recovery and improved quality of life. The Medical and Surgical Instruments segment includes a wide range of instruments for surgery, including surgical saws, scalpels, forceps, and other instruments for various surgical procedures. These instruments are used by physicians for a variety of surgical interventions. In the Neurotechnology and Spine Products segment, Stryker develops and distributes products for spinal surgery, including implants for intervertebral discs and for stabilization of the cervical and lumbar spine. In addition to selling products, Stryker also offers medical services. This includes consulting and support for the implementation of products and systems in hospitals and medical facilities. Technical support and customer service are also part of the offerings. Stryker's business model is based on its ability to develop and produce innovative and high-quality products for the medical field. The company emphasizes close collaboration with medical professionals to ensure that the offered products meet the requirements of the practice and enable optimal treatment for patients. The company also strives to continuously improve its products and develop new technologies. In particular, the introduction of robotics in surgery offers Stryker significant growth opportunities as it has the potential for higher efficiency, precision, and better treatment outcomes. Overall, Stryker is a leading company in the medical technology industry, specializing in the development of innovative products and the provision of high-quality medical services. The company has a wide range of products in various business segments, including Medical Devices, Orthopedics, Medical and Surgical Instruments, and Neurotechnology and Spine Products. Stryker's business model is based on serving medical professionals with high-quality products and services and developing innovative technologies to achieve even better treatment outcomes for patients.
The expected revenue of Stryker is 27.30 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Stryker is 5.81 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Stryker is currently 17.96. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Stryker stock.
The price-to-sales ratio (P/S) of Stryker is currently 3.82. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Stryker stock.
The Eulerpool Quality Score for Stryker is 8/10.
The ISIN of Stryker is US8636671013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Stryker is 864952. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Stryker is SYK. The ticker symbol is used to trade Stryker shares on the stock exchange.
Over the past 12 months, Stryker paid a dividend of 3.40 USD . This corresponds to a dividend yield of about 1.26 %. For the coming 12 months, Stryker is expected to pay a dividend of 3.79 USD.
The current dividend yield of Stryker is 1.26 %.
Stryker pays a dividend, distributed in the months of , , , .
Stryker paid dividends every year for the past 29 years.
For the upcoming 12 months, dividends amounting to 3.79 USD are expected. This corresponds to a dividend yield of 1.38 %.
Stryker is assigned to the 'Health' sector.
To receive the latest dividend of Stryker from amounting to 0.88 USD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
In the year 2025, Stryker distributed 3.24 USD as dividends.
The dividends of Stryker are distributed in USD.
Stryker stock
Stryker Peer Group
Stryker Ticker
Stryker FIGI
All fundamentals and in-depth analysis of Stryker
Our stock analysis for Stryker stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stryker. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.